

Global Varicella Attenuated Live Vaccine Market Growth 2024-2030

<https://marketpublishers.com/r/G7D0DB7A03BEN.html>

Date: January 2024

Pages: 99

Price: US\$ 3,660.00 (Single User License)

ID: G7D0DB7A03BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

According to our LPI (LP Information) latest study, the global Varicella Attenuated Live Vaccine market size was valued at US\$ 2498.1 million in 2023. With growing demand in downstream market, the Varicella Attenuated Live Vaccine is forecast to a readjusted size of US\$ 3390.6 million by 2030 with a CAGR of 4.5% during review period.

The research report highlights the growth potential of the global Varicella Attenuated Live Vaccine market. Varicella Attenuated Live Vaccine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Varicella Attenuated Live Vaccine. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Varicella Attenuated Live Vaccine market.

A live attenuated varicella vaccine, derived from the Oka strain of VZV has clinical efficacy for the prevention of varicella.

For the major players of Varicella Attenuated Live Vaccine, Merck maintained its first place in the ranking in 2019, followed by BCHT, Shanghai Institute, GSK and Keygen. Top 5 players accounted for about 95% of the Global Varicella Attenuated Live Vaccine revenue market share in 2019.

The sales market for Varicella Attenuated Live Vaccine was divided into five geographic regions. Asia-Pacific occupied the largest sales market share with about 58% in 2019. It

is followed by North America and Europe with about 18% and about 13% respectively, while other regions have smaller market.

Key Features:

The report on Varicella Attenuated Live Vaccine market reflects various aspects and provide valuable insights into the industry.

Market Size and Growth: The research report provide an overview of the current size and growth of the Varicella Attenuated Live Vaccine market. It may include historical data, market segmentation by Type (e.g., Monovalent Vaccine, Combination Vaccine), and regional breakdowns.

Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Varicella Attenuated Live Vaccine market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.

Competitive Landscape: The research report provides analysis of the competitive landscape within the Varicella Attenuated Live Vaccine market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.

Technological Developments: The research report can delve into the latest technological developments in the Varicella Attenuated Live Vaccine industry. This include advancements in Varicella Attenuated Live Vaccine technology, Varicella Attenuated Live Vaccine new entrants, Varicella Attenuated Live Vaccine new investment, and other innovations that are shaping the future of Varicella Attenuated Live Vaccine.

Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Varicella Attenuated Live Vaccine market. It includes factors influencing customer ' purchasing decisions, preferences for Varicella Attenuated Live Vaccine product.

Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Varicella Attenuated Live Vaccine market. This may include an assessment of regulatory frameworks, subsidies, tax incentives,

and other measures aimed at promoting Varicella Attenuated Live Vaccine market. The report also evaluates the effectiveness of these policies in driving market growth.

Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Varicella Attenuated Live Vaccine market.

Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Varicella Attenuated Live Vaccine industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.

Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Varicella Attenuated Live Vaccine market.

Market Segmentation:

Varicella Attenuated Live Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Segmentation by type

Monovalent Vaccine

Combination Vaccine

Segmentation by application

Kids Injection

Adults Injection

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Merck

BCHT

Shanghai Institute

GSK

Keygen

Green Cross

Biken

Shanghai Rongsheng Biotech

Changchun Changsheng Life Sciences Limited

Key Questions Addressed in this Report

What is the 10-year outlook for the global Varicella Attenuated Live Vaccine market?

What factors are driving Varicella Attenuated Live Vaccine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Varicella Attenuated Live Vaccine market opportunities vary by end market size?

How does Varicella Attenuated Live Vaccine break out type, application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Varicella Attenuated Live Vaccine Annual Sales 2019-2030
- 2.1.2 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Geographic Region, 2019, 2023 & 2030
- 2.1.3 World Current & Future Analysis for Varicella Attenuated Live Vaccine by Country/Region, 2019, 2023 & 2030

2.2 Varicella Attenuated Live Vaccine Segment by Type

- 2.2.1 Monovalent Vaccine
- 2.2.2 Combination Vaccine

2.3 Varicella Attenuated Live Vaccine Sales by Type

- 2.3.1 Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)
- 2.3.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Type (2019-2024)
- 2.3.3 Global Varicella Attenuated Live Vaccine Sale Price by Type (2019-2024)

2.4 Varicella Attenuated Live Vaccine Segment by Application

- 2.4.1 Kids Injection
- 2.4.2 Adults Injection

2.5 Varicella Attenuated Live Vaccine Sales by Application

- 2.5.1 Global Varicella Attenuated Live Vaccine Sale Market Share by Application (2019-2024)
- 2.5.2 Global Varicella Attenuated Live Vaccine Revenue and Market Share by Application (2019-2024)
- 2.5.3 Global Varicella Attenuated Live Vaccine Sale Price by Application (2019-2024)

3 GLOBAL VARICELLA ATTENUATED LIVE VACCINE BY COMPANY

- 3.1 Global Varicella Attenuated Live Vaccine Breakdown Data by Company
 - 3.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Company (2019-2024)
 - 3.1.2 Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2019-2024)
- 3.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Company (2019-2024)
 - 3.2.1 Global Varicella Attenuated Live Vaccine Revenue by Company (2019-2024)
 - 3.2.2 Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2019-2024)
- 3.3 Global Varicella Attenuated Live Vaccine Sale Price by Company
- 3.4 Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution, Sales Area, Product Type
 - 3.4.1 Key Manufacturers Varicella Attenuated Live Vaccine Product Location Distribution
 - 3.4.2 Players Varicella Attenuated Live Vaccine Products Offered
- 3.5 Market Concentration Rate Analysis
 - 3.5.1 Competition Landscape Analysis
 - 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
- 3.6 New Products and Potential Entrants
- 3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION

- 4.1 World Historic Varicella Attenuated Live Vaccine Market Size by Geographic Region (2019-2024)
 - 4.1.1 Global Varicella Attenuated Live Vaccine Annual Sales by Geographic Region (2019-2024)
 - 4.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Geographic Region (2019-2024)
- 4.2 World Historic Varicella Attenuated Live Vaccine Market Size by Country/Region (2019-2024)
 - 4.2.1 Global Varicella Attenuated Live Vaccine Annual Sales by Country/Region (2019-2024)
 - 4.2.2 Global Varicella Attenuated Live Vaccine Annual Revenue by Country/Region (2019-2024)

- 4.3 Americas Varicella Attenuated Live Vaccine Sales Growth
- 4.4 APAC Varicella Attenuated Live Vaccine Sales Growth
- 4.5 Europe Varicella Attenuated Live Vaccine Sales Growth
- 4.6 Middle East & Africa Varicella Attenuated Live Vaccine Sales Growth

5 AMERICAS

- 5.1 Americas Varicella Attenuated Live Vaccine Sales by Country
 - 5.1.1 Americas Varicella Attenuated Live Vaccine Sales by Country (2019-2024)
 - 5.1.2 Americas Varicella Attenuated Live Vaccine Revenue by Country (2019-2024)
- 5.2 Americas Varicella Attenuated Live Vaccine Sales by Type
- 5.3 Americas Varicella Attenuated Live Vaccine Sales by Application
- 5.4 United States
- 5.5 Canada
- 5.6 Mexico
- 5.7 Brazil

6 APAC

- 6.1 APAC Varicella Attenuated Live Vaccine Sales by Region
 - 6.1.1 APAC Varicella Attenuated Live Vaccine Sales by Region (2019-2024)
 - 6.1.2 APAC Varicella Attenuated Live Vaccine Revenue by Region (2019-2024)
- 6.2 APAC Varicella Attenuated Live Vaccine Sales by Type
- 6.3 APAC Varicella Attenuated Live Vaccine Sales by Application
- 6.4 China
- 6.5 Japan
- 6.6 South Korea
- 6.7 Southeast Asia
- 6.8 India
- 6.9 Australia
- 6.10 China Taiwan

7 EUROPE

- 7.1 Europe Varicella Attenuated Live Vaccine by Country
 - 7.1.1 Europe Varicella Attenuated Live Vaccine Sales by Country (2019-2024)
 - 7.1.2 Europe Varicella Attenuated Live Vaccine Revenue by Country (2019-2024)
- 7.2 Europe Varicella Attenuated Live Vaccine Sales by Type
- 7.3 Europe Varicella Attenuated Live Vaccine Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Varicella Attenuated Live Vaccine by Country

8.1.1 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2019-2024)

8.1.2 Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2019-2024)

8.2 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type

8.3 Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine

10.3 Manufacturing Process Analysis of Varicella Attenuated Live Vaccine

10.4 Industry Chain Structure of Varicella Attenuated Live Vaccine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Varicella Attenuated Live Vaccine Distributors

11.3 Varicella Attenuated Live Vaccine Customer

12 WORLD FORECAST REVIEW FOR VARICELLA ATTENUATED LIVE VACCINE BY GEOGRAPHIC REGION

12.1 Global Varicella Attenuated Live Vaccine Market Size Forecast by Region

12.1.1 Global Varicella Attenuated Live Vaccine Forecast by Region (2025-2030)

12.1.2 Global Varicella Attenuated Live Vaccine Annual Revenue Forecast by Region (2025-2030)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Varicella Attenuated Live Vaccine Forecast by Type

12.7 Global Varicella Attenuated Live Vaccine Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Merck

13.1.1 Merck Company Information

13.1.2 Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications

13.1.3 Merck Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

13.1.4 Merck Main Business Overview

13.1.5 Merck Latest Developments

13.2 BCHT

13.2.1 BCHT Company Information

13.2.2 BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications

13.2.3 BCHT Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

13.2.4 BCHT Main Business Overview

13.2.5 BCHT Latest Developments

13.3 Shanghai Institute

13.3.1 Shanghai Institute Company Information

13.3.2 Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications

13.3.3 Shanghai Institute Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

- 13.3.4 Shanghai Institute Main Business Overview
- 13.3.5 Shanghai Institute Latest Developments
- 13.4 GSK
 - 13.4.1 GSK Company Information
 - 13.4.2 GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications
 - 13.4.3 GSK Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.4.4 GSK Main Business Overview
 - 13.4.5 GSK Latest Developments
- 13.5 Keygen
 - 13.5.1 Keygen Company Information
 - 13.5.2 Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications
 - 13.5.3 Keygen Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.5.4 Keygen Main Business Overview
 - 13.5.5 Keygen Latest Developments
- 13.6 Green Cross
 - 13.6.1 Green Cross Company Information
 - 13.6.2 Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications
 - 13.6.3 Green Cross Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.6.4 Green Cross Main Business Overview
 - 13.6.5 Green Cross Latest Developments
- 13.7 Biken
 - 13.7.1 Biken Company Information
 - 13.7.2 Biken Varicella Attenuated Live Vaccine Product Portfolios and Specifications
 - 13.7.3 Biken Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.7.4 Biken Main Business Overview
 - 13.7.5 Biken Latest Developments
- 13.8 Shanghai Rongsheng Biotech
 - 13.8.1 Shanghai Rongsheng Biotech Company Information
 - 13.8.2 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications
 - 13.8.3 Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)
 - 13.8.4 Shanghai Rongsheng Biotech Main Business Overview
 - 13.8.5 Shanghai Rongsheng Biotech Latest Developments

13.9 Changchun Changsheng Life Sciences Limited

13.9.1 Changchun Changsheng Life Sciences Limited Company Information

13.9.2 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications

13.9.3 Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2019-2024)

13.9.4 Changchun Changsheng Life Sciences Limited Main Business Overview

13.9.5 Changchun Changsheng Life Sciences Limited Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Varicella Attenuated Live Vaccine Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & (\$ millions)
- Table 2. Varicella Attenuated Live Vaccine Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & (\$ millions)
- Table 3. Major Players of Monovalent Vaccine
- Table 4. Major Players of Combination Vaccine
- Table 5. Global Varicella Attenuated Live Vaccine Sales by Type (2019-2024) & (K Doses)
- Table 6. Global Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)
- Table 7. Global Varicella Attenuated Live Vaccine Revenue by Type (2019-2024) & (\$ million)
- Table 8. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2019-2024)
- Table 9. Global Varicella Attenuated Live Vaccine Sale Price by Type (2019-2024) & (USD/Dose)
- Table 10. Global Varicella Attenuated Live Vaccine Sales by Application (2019-2024) & (K Doses)
- Table 11. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)
- Table 12. Global Varicella Attenuated Live Vaccine Revenue by Application (2019-2024)
- Table 13. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application (2019-2024)
- Table 14. Global Varicella Attenuated Live Vaccine Sale Price by Application (2019-2024) & (USD/Dose)
- Table 15. Global Varicella Attenuated Live Vaccine Sales by Company (2019-2024) & (K Doses)
- Table 16. Global Varicella Attenuated Live Vaccine Sales Market Share by Company (2019-2024)
- Table 17. Global Varicella Attenuated Live Vaccine Revenue by Company (2019-2024) (\$ Millions)
- Table 18. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company (2019-2024)
- Table 19. Global Varicella Attenuated Live Vaccine Sale Price by Company (2019-2024)

& (USD/Dose)

Table 20. Key Manufacturers Varicella Attenuated Live Vaccine Producing Area Distribution and Sales Area

Table 21. Players Varicella Attenuated Live Vaccine Products Offered

Table 22. Varicella Attenuated Live Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Varicella Attenuated Live Vaccine Sales by Geographic Region (2019-2024) & (K Doses)

Table 26. Global Varicella Attenuated Live Vaccine Sales Market Share Geographic Region (2019-2024)

Table 27. Global Varicella Attenuated Live Vaccine Revenue by Geographic Region (2019-2024) & (\$ millions)

Table 28. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region (2019-2024)

Table 29. Global Varicella Attenuated Live Vaccine Sales by Country/Region (2019-2024) & (K Doses)

Table 30. Global Varicella Attenuated Live Vaccine Sales Market Share by Country/Region (2019-2024)

Table 31. Global Varicella Attenuated Live Vaccine Revenue by Country/Region (2019-2024) & (\$ millions)

Table 32. Global Varicella Attenuated Live Vaccine Revenue Market Share by Country/Region (2019-2024)

Table 33. Americas Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 34. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2024)

Table 35. Americas Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (\$ Millions)

Table 36. Americas Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2024)

Table 37. Americas Varicella Attenuated Live Vaccine Sales by Type (2019-2024) & (K Doses)

Table 38. Americas Varicella Attenuated Live Vaccine Sales by Application (2019-2024) & (K Doses)

Table 39. APAC Varicella Attenuated Live Vaccine Sales by Region (2019-2024) & (K Doses)

Table 40. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region

(2019-2024)

Table 41. APAC Varicella Attenuated Live Vaccine Revenue by Region (2019-2024) & (\$ Millions)

Table 42. APAC Varicella Attenuated Live Vaccine Revenue Market Share by Region (2019-2024)

Table 43. APAC Varicella Attenuated Live Vaccine Sales by Type (2019-2024) & (K Doses)

Table 44. APAC Varicella Attenuated Live Vaccine Sales by Application (2019-2024) & (K Doses)

Table 45. Europe Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 46. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2024)

Table 47. Europe Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (\$ Millions)

Table 48. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2024)

Table 49. Europe Varicella Attenuated Live Vaccine Sales by Type (2019-2024) & (K Doses)

Table 50. Europe Varicella Attenuated Live Vaccine Sales by Application (2019-2024) & (K Doses)

Table 51. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Country (2019-2024) & (K Doses)

Table 52. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Country (2019-2024)

Table 53. Middle East & Africa Varicella Attenuated Live Vaccine Revenue by Country (2019-2024) & (\$ Millions)

Table 54. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Market Share by Country (2019-2024)

Table 55. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Type (2019-2024) & (K Doses)

Table 56. Middle East & Africa Varicella Attenuated Live Vaccine Sales by Application (2019-2024) & (K Doses)

Table 57. Key Market Drivers & Growth Opportunities of Varicella Attenuated Live Vaccine

Table 58. Key Market Challenges & Risks of Varicella Attenuated Live Vaccine

Table 59. Key Industry Trends of Varicella Attenuated Live Vaccine

Table 60. Varicella Attenuated Live Vaccine Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Varicella Attenuated Live Vaccine Distributors List

Table 63. Varicella Attenuated Live Vaccine Customer List

Table 64. Global Varicella Attenuated Live Vaccine Sales Forecast by Region (2025-2030) & (K Doses)

Table 65. Global Varicella Attenuated Live Vaccine Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 66. Americas Varicella Attenuated Live Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 67. Americas Varicella Attenuated Live Vaccine Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 68. APAC Varicella Attenuated Live Vaccine Sales Forecast by Region (2025-2030) & (K Doses)

Table 69. APAC Varicella Attenuated Live Vaccine Revenue Forecast by Region (2025-2030) & (\$ millions)

Table 70. Europe Varicella Attenuated Live Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 71. Europe Varicella Attenuated Live Vaccine Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 72. Middle East & Africa Varicella Attenuated Live Vaccine Sales Forecast by Country (2025-2030) & (K Doses)

Table 73. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Forecast by Country (2025-2030) & (\$ millions)

Table 74. Global Varicella Attenuated Live Vaccine Sales Forecast by Type (2025-2030) & (K Doses)

Table 75. Global Varicella Attenuated Live Vaccine Revenue Forecast by Type (2025-2030) & (\$ Millions)

Table 76. Global Varicella Attenuated Live Vaccine Sales Forecast by Application (2025-2030) & (K Doses)

Table 77. Global Varicella Attenuated Live Vaccine Revenue Forecast by Application (2025-2030) & (\$ Millions)

Table 78. Merck Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 79. Merck Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 80. Merck Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 81. Merck Main Business

Table 82. Merck Latest Developments

Table 83. BCHAT Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 84. BCHT Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 85. BCHT Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 86. BCHT Main Business

Table 87. BCHT Latest Developments

Table 88. Shanghai Institute Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 89. Shanghai Institute Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 90. Shanghai Institute Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 91. Shanghai Institute Main Business

Table 92. Shanghai Institute Latest Developments

Table 93. GSK Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 94. GSK Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 95. GSK Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 96. GSK Main Business

Table 97. GSK Latest Developments

Table 98. Keygen Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 99. Keygen Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 100. Keygen Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 101. Keygen Main Business

Table 102. Keygen Latest Developments

Table 103. Green Cross Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 104. Green Cross Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 105. Green Cross Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 106. Green Cross Main Business

Table 107. Green Cross Latest Developments

Table 108. Biken Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 109. Biken Varicella Attenuated Live Vaccine Product Portfolios and

Specifications

Table 110. Biken Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 111. Biken Main Business

Table 112. Biken Latest Developments

Table 113. Shanghai Rongsheng Biotech Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 114. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 115. Shanghai Rongsheng Biotech Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 116. Shanghai Rongsheng Biotech Main Business

Table 117. Shanghai Rongsheng Biotech Latest Developments

Table 118. Changchun Changsheng Life Sciences Limited Basic Information, Varicella Attenuated Live Vaccine Manufacturing Base, Sales Area and Its Competitors

Table 119. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Product Portfolios and Specifications

Table 120. Changchun Changsheng Life Sciences Limited Varicella Attenuated Live Vaccine Sales (K Doses), Revenue (\$ Million), Price (USD/Dose) and Gross Margin (2019-2024)

Table 121. Changchun Changsheng Life Sciences Limited Main Business

Table 122. Changchun Changsheng Life Sciences Limited Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Varicella Attenuated Live Vaccine
- Figure 2. Varicella Attenuated Live Vaccine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Varicella Attenuated Live Vaccine Sales Growth Rate 2019-2030 (K Doses)
- Figure 7. Global Varicella Attenuated Live Vaccine Revenue Growth Rate 2019-2030 (\$ Millions)
- Figure 8. Varicella Attenuated Live Vaccine Sales by Region (2019, 2023 & 2030) & (\$ Millions)
- Figure 9. Product Picture of Monovalent Vaccine
- Figure 10. Product Picture of Combination Vaccine
- Figure 11. Global Varicella Attenuated Live Vaccine Sales Market Share by Type in 2023
- Figure 12. Global Varicella Attenuated Live Vaccine Revenue Market Share by Type (2019-2024)
- Figure 13. Varicella Attenuated Live Vaccine Consumed in Kids Injection
- Figure 14. Global Varicella Attenuated Live Vaccine Market: Kids Injection (2019-2024) & (K Doses)
- Figure 15. Varicella Attenuated Live Vaccine Consumed in Adults Injection
- Figure 16. Global Varicella Attenuated Live Vaccine Market: Adults Injection (2019-2024) & (K Doses)
- Figure 17. Global Varicella Attenuated Live Vaccine Sales Market Share by Application (2023)
- Figure 18. Global Varicella Attenuated Live Vaccine Revenue Market Share by Application in 2023
- Figure 19. Varicella Attenuated Live Vaccine Sales Market by Company in 2023 (K Doses)
- Figure 20. Global Varicella Attenuated Live Vaccine Sales Market Share by Company in 2023
- Figure 21. Varicella Attenuated Live Vaccine Revenue Market by Company in 2023 (\$ Million)
- Figure 22. Global Varicella Attenuated Live Vaccine Revenue Market Share by Company in 2023

Figure 23. Global Varicella Attenuated Live Vaccine Sales Market Share by Geographic Region (2019-2024)

Figure 24. Global Varicella Attenuated Live Vaccine Revenue Market Share by Geographic Region in 2023

Figure 25. Americas Varicella Attenuated Live Vaccine Sales 2019-2024 (K Doses)

Figure 26. Americas Varicella Attenuated Live Vaccine Revenue 2019-2024 (\$ Millions)

Figure 27. APAC Varicella Attenuated Live Vaccine Sales 2019-2024 (K Doses)

Figure 28. APAC Varicella Attenuated Live Vaccine Revenue 2019-2024 (\$ Millions)

Figure 29. Europe Varicella Attenuated Live Vaccine Sales 2019-2024 (K Doses)

Figure 30. Europe Varicella Attenuated Live Vaccine Revenue 2019-2024 (\$ Millions)

Figure 31. Middle East & Africa Varicella Attenuated Live Vaccine Sales 2019-2024 (K Doses)

Figure 32. Middle East & Africa Varicella Attenuated Live Vaccine Revenue 2019-2024 (\$ Millions)

Figure 33. Americas Varicella Attenuated Live Vaccine Sales Market Share by Country in 2023

Figure 34. Americas Varicella Attenuated Live Vaccine Revenue Market Share by Country in 2023

Figure 35. Americas Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)

Figure 36. Americas Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)

Figure 37. United States Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 38. Canada Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 39. Mexico Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 40. Brazil Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 41. APAC Varicella Attenuated Live Vaccine Sales Market Share by Region in 2023

Figure 42. APAC Varicella Attenuated Live Vaccine Revenue Market Share by Regions in 2023

Figure 43. APAC Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)

Figure 44. APAC Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)

Figure 45. China Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$

Millions)

Figure 46. Japan Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 47. South Korea Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 48. Southeast Asia Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 49. India Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 50. Australia Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 51. China Taiwan Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 52. Europe Varicella Attenuated Live Vaccine Sales Market Share by Country in 2023

Figure 53. Europe Varicella Attenuated Live Vaccine Revenue Market Share by Country in 2023

Figure 54. Europe Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)

Figure 55. Europe Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)

Figure 56. Germany Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 57. France Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 58. UK Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 59. Italy Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 60. Russia Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 61. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Country in 2023

Figure 62. Middle East & Africa Varicella Attenuated Live Vaccine Revenue Market Share by Country in 2023

Figure 63. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Type (2019-2024)

Figure 64. Middle East & Africa Varicella Attenuated Live Vaccine Sales Market Share by Application (2019-2024)

Figure 65. Egypt Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 66. South Africa Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 67. Israel Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 68. Turkey Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 69. GCC Country Varicella Attenuated Live Vaccine Revenue Growth 2019-2024 (\$ Millions)

Figure 70. Manufacturing Cost Structure Analysis of Varicella Attenuated Live Vaccine in 2023

Figure 71. Manufacturing Process Analysis of Varicella Attenuated Live Vaccine

Figure 72. Industry Chain Structure of Varicella Attenuated Live Vaccine

Figure 73. Channels of Distribution

Figure 74. Global Varicella Attenuated Live Vaccine Sales Market Forecast by Region (2025-2030)

Figure 75. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Region (2025-2030)

Figure 76. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Type (2025-2030)

Figure 77. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Type (2025-2030)

Figure 78. Global Varicella Attenuated Live Vaccine Sales Market Share Forecast by Application (2025-2030)

Figure 79. Global Varicella Attenuated Live Vaccine Revenue Market Share Forecast by Application (2025-2030)

I would like to order

Product name: Global Varicella Attenuated Live Vaccine Market Growth 2024-2030

Product link: <https://marketpublishers.com/r/G7D0DB7A03BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G7D0DB7A03BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970